Stock Analysis on Net
Stock Analysis on Net

GlaxoSmithKline PLC (NYSE:GSK)

$22.49

This company has been moved to the archive! The financial data has not been updated since February 27, 2015.

Analysis of Investments

Microsoft Excel

Paying users area

Try for free

GlaxoSmithKline PLC pages available for free this week:

The data is hidden behind: . Unhide it.

  • Get 1-month access to GlaxoSmithKline PLC for $22.49, or

  • get full access to the entire website for at least 3 months from $62.19.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Adjustment to Net Income (Loss): Mark to Market Available-for-sale Securities

GlaxoSmithKline PLC, adjustment to profit attributable to shareholders

US$ in millions, translated from GBP £

Microsoft Excel
12 months ended: Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Profit attributable to shareholders (as reported)
Add: Fair value movements on available-for-sale investments
Less: Reclassification of fair value movements on available-for-sale investments
Profit attributable to shareholders (adjusted)

Based on: 20-F (reporting date: 2014-12-31), 20-F (reporting date: 2013-12-31), 20-F (reporting date: 2012-12-31), 20-F (reporting date: 2011-12-31), 20-F (reporting date: 2010-12-31).

Adjusted Profitability Ratios: Mark to Market Available-for-sale Securities (Summary)

GlaxoSmithKline PLC, adjusted profitability ratios

Microsoft Excel
Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Net Profit Margin
Reported net profit margin
Adjusted net profit margin
Return on Equity (ROE)
Reported ROE
Adjusted ROE
Return on Assets (ROA)
Reported ROA
Adjusted ROA

Based on: 20-F (reporting date: 2014-12-31), 20-F (reporting date: 2013-12-31), 20-F (reporting date: 2012-12-31), 20-F (reporting date: 2011-12-31), 20-F (reporting date: 2010-12-31).

Profitability ratio Description The company
Adjusted net profit margin An indicator of profitability, calculated as adjusted net income divided by revenue. GlaxoSmithKline PLC adjusted net profit margin ratio improved from 2012 to 2013 but then deteriorated significantly from 2013 to 2014.
Adjusted ROE A profitability ratio calculated as adjusted net income divided by shareholders’ equity. GlaxoSmithKline PLC adjusted ROE improved from 2012 to 2013 but then deteriorated significantly from 2013 to 2014.
Adjusted ROA A profitability ratio calculated as adjusted net income divided by total assets. GlaxoSmithKline PLC adjusted ROA improved from 2012 to 2013 but then deteriorated significantly from 2013 to 2014.

GlaxoSmithKline PLC, Profitability Ratios: Reported vs. Adjusted

Adjusted Net Profit Margin

Microsoft Excel
Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
As Reported
Selected Financial Data (US$ in millions, translated from GBP £)
Profit attributable to shareholders
Turnover
Profitability Ratio
Net profit margin1
Adjusted: Mark to Market Available-for-sale Securities
Selected Financial Data (US$ in millions, translated from GBP £)
Adjusted profit attributable to shareholders
Turnover
Profitability Ratio
Adjusted net profit margin2

Based on: 20-F (reporting date: 2014-12-31), 20-F (reporting date: 2013-12-31), 20-F (reporting date: 2012-12-31), 20-F (reporting date: 2011-12-31), 20-F (reporting date: 2010-12-31).

2014 Calculations

1 Net profit margin = 100 × Profit attributable to shareholders ÷ Turnover
= 100 × ÷ =

2 Adjusted net profit margin = 100 × Adjusted profit attributable to shareholders ÷ Turnover
= 100 × ÷ =

Profitability ratio Description The company
Adjusted net profit margin An indicator of profitability, calculated as adjusted net income divided by revenue. GlaxoSmithKline PLC adjusted net profit margin ratio improved from 2012 to 2013 but then deteriorated significantly from 2013 to 2014.

Adjusted Return on Equity (ROE)

Microsoft Excel
Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
As Reported
Selected Financial Data (US$ in millions, translated from GBP £)
Profit attributable to shareholders
Shareholders’ equity
Profitability Ratio
ROE1
Adjusted: Mark to Market Available-for-sale Securities
Selected Financial Data (US$ in millions, translated from GBP £)
Adjusted profit attributable to shareholders
Shareholders’ equity
Profitability Ratio
Adjusted ROE2

Based on: 20-F (reporting date: 2014-12-31), 20-F (reporting date: 2013-12-31), 20-F (reporting date: 2012-12-31), 20-F (reporting date: 2011-12-31), 20-F (reporting date: 2010-12-31).

2014 Calculations

1 ROE = 100 × Profit attributable to shareholders ÷ Shareholders’ equity
= 100 × ÷ =

2 Adjusted ROE = 100 × Adjusted profit attributable to shareholders ÷ Shareholders’ equity
= 100 × ÷ =

Profitability ratio Description The company
Adjusted ROE A profitability ratio calculated as adjusted net income divided by shareholders’ equity. GlaxoSmithKline PLC adjusted ROE improved from 2012 to 2013 but then deteriorated significantly from 2013 to 2014.

Adjusted Return on Assets (ROA)

Microsoft Excel
Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
As Reported
Selected Financial Data (US$ in millions, translated from GBP £)
Profit attributable to shareholders
Total assets
Profitability Ratio
ROA1
Adjusted: Mark to Market Available-for-sale Securities
Selected Financial Data (US$ in millions, translated from GBP £)
Adjusted profit attributable to shareholders
Total assets
Profitability Ratio
Adjusted ROA2

Based on: 20-F (reporting date: 2014-12-31), 20-F (reporting date: 2013-12-31), 20-F (reporting date: 2012-12-31), 20-F (reporting date: 2011-12-31), 20-F (reporting date: 2010-12-31).

2014 Calculations

1 ROA = 100 × Profit attributable to shareholders ÷ Total assets
= 100 × ÷ =

2 Adjusted ROA = 100 × Adjusted profit attributable to shareholders ÷ Total assets
= 100 × ÷ =

Profitability ratio Description The company
Adjusted ROA A profitability ratio calculated as adjusted net income divided by total assets. GlaxoSmithKline PLC adjusted ROA improved from 2012 to 2013 but then deteriorated significantly from 2013 to 2014.